Mangoceuticals Inc. recently completed two notable share transactions. On July 29, 2025, a holder of outstanding warrants exercised the option to purchase 198,000 shares of common stock at an exercise price of $1.50 per share, totaling $297,000. Additionally, as part of a Mutual Rescission and Release Agreement with Navy Wharf on July 30, 2025, Navy Wharf agreed to cancel 1,000,000 shares of Mangoceuticals' restricted common stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.